The National Medical Products Administration, via its priority review channel,
has granted conditional approval to Chengdu Bailiduote Biopharma Co., Ltd.'s
injectable monoclonal antibody Lunkangyilongtuo (trade name Yizekang).
Indication: adults with recurrent or metastatic nasopharyngeal carcinoma who
progressed after at least two lines of systemic chemotherapy and prior
PD‑1/PD‑L1 inhibitor therapy. The approval adds a new treatment option for this
patient cohort.
